Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Clinical trial NCT05735080 · RECRUITING

Trial details

NCT number: NCT05735080
Sponsor: Incyclix Bio
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Breast Cancer Breast Cancer Metastatic Hormone Receptor Positive Tumor Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Ovarian Cancer CCNE1 Amplification Solid Tumor Advanced Cancer Metastatic Cancer

Start date: 2023-03-28
Primary completion: 2027-07-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.